Update on the second line management of idiopathic overactive bladder;Le point sur les traitements de seconde ligne de l'hyperactivité vésicale idiopathique

Progres en Urologie

Volumn 19, Issue 8, 2009, Pages 530-537

  Chartier Kastler, E ^g   Castro Diaz, D ^a   De Ridder, D ^b   Everaert, K ^c   Sievert, K D ^d   Spinelli, M ^e   van Kerrebroeck, P ^f  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Botulinum toxin A; Overactive bladder; Sacral neuromodulation; Urge urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ELECTROSTIMULATION THERAPY; HUMAN; OVERACTIVE BLADDER; SHORT SURVEY;

BOTULINUM TOXIN TYPE A; ELECTRIC STIMULATION THERAPY; HUMANS; NEUROMUSCULAR AGENTS; URINARY BLADDER, OVERACTIVE;

EID: 68949175005     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.02.001     Document Type: Short Survey

References (44)

1. Abrams P.A.K., Brubaker L., et al. Recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abrams P.C.L., Khoury S., and Wein A. (Eds). Incontinence (2005), Health Publication Ltd, Plymouth, England 1589-1630
2. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., and Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
3. Stewart W.F., Van Rooyen J.B., Cundiff G.W., Abrams P., Herzog A.R., Corey R., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
4. Jackson S. The patient with an overactive bladder-symptoms and quality-of-life issues. Urology 50 (1997) 18-22
5. Gallup Inc. Gallup Study of the Market for Prescription Incontinence Medication. In: Multi-sponsor Survey. Eds Princeton, NJ:2002.
6. South M.M., Romero A.A., Jamison M.G., Webster G.D., and Amundsen C.L. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct 18 (2007) 1395-1398
7. Apostolidis A., Dasgupta P., and Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49 (2006) 644-650
8. Sahai A., Khan M.S., and Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177 (2007) 2231-2236
9. Ghalayini I.F., and Al-Ghazo M.A. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 26 (2007) 531-536
10. Kalsi V., Apostolidis A., Popat R., Gonzales G., Fowler C.J., and Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49 (2006) 528-535
11. Popat R., Apostolidis A., Kalsi V., Gonzales G., Fowler C.J., and Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174 (2005) 984-989
12. Rajkumar G.N., Small D.R., Mustafa A.W., and Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96 (2005) 848-852
13. Kessler T.M., Danuser H., Schumacher M., Studer U.E., and Burkhard F.C. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 24 (2005) 231-236
14. Karsenty G., Elzayat E., Delapparent T., St-Denis B., Lemieux M.C., and Corcos J. Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 177 (2007) 1011-1014
15. Lucioni A., Rapp D.E., Gong E.M., Fedunok P., and Bales G.T. Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 13 (2006) 3291-3295
16. Kuo H.C. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 178 (2007) 1359-1363
17. Harper M., Popat R.B., Dasgupta R., Fowler C.J., and Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92 (2003) 325-326
18. Hampel C., Pahernik S., Gillitzer R., Melcbior S., and Thüroff J. Botulinum toxin detrusor injections in patients with non-neurogenic bladder hyperactivity. Eur Urol 4 (2005) 61
19. Schmid D.M., Sauermann P., Werner M., Schuessler B., Blick N., Muentener M., et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176 (2006) 177-185
20. Patel A.K., Patterson J.M., and Chapple C.R. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 50 (2006) 684-709 [discussion 709-10]
21. Dmochowski R.S., and Sand P.K. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int 99 (2007) 247-262
22. van der Pal F., Heesakkers J.P., and Bemelmans B.L. Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction. Curr Opin Urol 16 (2006) 261-267
23. Chancellor M., and Chartier-Kastler E. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromodulation 3 (2000) 16-26
24. Schmidt R.A., Jonas U., Oleson K.A., Janknegt R.A., Hassouna M.M., Siegel S.W., et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral nerve stimulation study group. J Urol 162 (1999) 352-357
25. Weil E.H., Ruiz-Cerda J.L., Eerdmans P.H., Janknegt R.A., Bemelmans B.L., and van Kerrebroeck P.E. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol 37 (2000) 161-171
26. Hassouna M.M., Siegel S.W., Nyeholt A.A., Elhilali M.M., van Kerrebroeck P.E., Das A.K., et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 163 (2000) 1849-1854
27. Siegel S.W., Catanzaro F., Dijkema H.E., Elhilali M.M., Fowler C.J., Gajewski J.B., et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 56 (2000) 87-91
28. Van Voskuilen A.C., Oerlemans D.J., Weil E.H., van den Hombergh U., and van Kerrebroeck P.E. Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int 99 (2007) 107-110
29. Leclers F., Mourey E., Galas J., Cormier L., and Mangin P. Étude cystomanométrique de la sensibilité vésicale sous test de neuromodulation sacrée. Prog Urol 15 (2005) 238-243
30. Ferhi K., Miaadi N., Tanneau Y., Leroy A., Sibert L., and Grise P. Résultats de la neuromodulation sacrée pour le traitement des troubles mictionnels chroniques et étude de son impact sur la sexualité : étude monocentrique. Prog Urol 18 (2008) 160-166
31. Starkman J.S., Wolter C.E., Scarpero H.M., Milam D.F., and Dmochowski R.R. Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation. Neurourol Urodyn 26 (2007) 29-35
32. Latini J.M., Alipour M., and Kreder Jr. K.J. Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology 67 (2006) 550-553
33. van Kerrebroeck P.E., van Voskuilen A.C., Heesakkers J.P., Lycklama a Nijholt A.A., Siegel S., Jonas U., et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 178 (2007) 2029-2034
34. Foster Sr. R.T., Anoia E.J., Webster G.D., and Amundsen C.L. In patients undergoing neuromodulation for intractable urge incontinence, a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn 26 (2007) 213-217
35. van Voskuilen A.C., Oerlemans D.J., Weil E.H., de Bie R.A., and van Kerrebroeck P.E. Long-term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol 49 (2006) 366-372
36. Spinelli M., and Sievert K. Latest technologic and surgical developments in using interstimtrade mark therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol 54 (2008) 1287-1296
37. Everaert K., Kerckhaert W., Caluwaerts H., Audenaert M., Vereecke H., De Cuypere G., et al. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur Urol 45 (2004) 649-654
38. Aboseif S., Tamaddon K., Chalfin S., Freedman S., and Kaptein J. Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology 60 (2002) 52-56
39. Khullar V., Damiano R., Toozs-Hobson P., and Cardozo L. Prevalence of faecal incontinence among women with urinary incontinence. Br J Obstet Gynaecol 105 (1998) 1211-1213
40. Jonas U., Fowler C.J., Chancellor M.B., Elhilali M.M., Fall M., Gajewski J.B., et al. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol 165 (2001) 15-19
41. Leroi A.M., Parc Y., Lehur P.A., Mion F., Barth X., Rullier E., et al. Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study. Ann Surg 242 (2005) 662-669
42. Kenefick N.J., Nicholls R.J., Cohen R.G., and Kamm M.A. Permanent sacral nerve stimulation for treatment of idiopathic constipation. Br J Surg 89 (2002) 882-888
43. Leroi A.M., Michot F., Grise P., and Denis P. Effect of sacral nerve stimulation in patients with fecal and urinary incontinence. Dis Colon Rectum 44 (2001) 779-789
44. Lombardi G., Mondaini N., Giubilei G., Macchiarella A., Lecconi F., and Del Popolo G. Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile dysfunction. J Sex Med 5 (2008) 2135-2140